{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:50:06Z","timestamp":1790412606522,"version":"4.1.0"},"reference-count":34,"publisher":"Harborside Press, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with MM. These NCCN Guidelines Insights highlight the important updates and changes specific to systemic therapy for patients with newly diagnosed as well as previously treated MM included in Version 1.2025 of the NCCN Guidelines for MM.<\/jats:p>","DOI":"10.6004\/jnccn.2025.0023","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T12:49:45Z","timestamp":1746708585000},"page":"132-140","source":"Crossref","is-referenced-by-count":58,"title":["NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 1.2025"],"prefix":"10.6004","volume":"23","author":[{"given":"Shaji K.","family":"Kumar","sequence":"first","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehinde","family":"Adekola","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamed","family":"Baljevic","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Campagnaro","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Costello","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Derman","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Devarakonda","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center\u2013James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Elsedawy","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Godara","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Godby","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo","family":"Htut","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Kang","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larson","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Omel","sequence":"additional","affiliation":[{"name":"Patient Advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Robinson","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sherbenou","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Valent","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asya Nina","family":"Varshavsky-Yanovsky","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Vogl","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Kovach","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kumar","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"SEER cancer stat facts: myeloma","unstructured":"National Cancer Institute. SEER cancer stat facts: myeloma. Accessed March 31, 2025. Available at https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"B2","series-title":"CA Cancer J Clin","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN,  Cancer statistics, 2025. CA Cancer J Clin 2025;75:10\u201345."},{"key":"B3","series-title":"BMC Public Health","first-page":"1054","article-title":"Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021","volume":"25","author":"Diao X","year":"2025","unstructured":"Diao X, Ben T, Cheng S,  Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021. BMC Public Health 2025;25:1054."},{"key":"B4","series-title":"N Engl J Med","first-page":"301","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld P","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M,  Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;390:301\u2013313."},{"key":"B5","series-title":"Lancet Haematol","first-page":"e825","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees PM","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J,  Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 2023;10:e825\u2013837."},{"key":"B6","series-title":"Blood Cancer J","first-page":"37","article-title":"Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Souto Filho JTD","year":"2025","unstructured":"Souto Filho JTD, Cantadori LO, Crusoe EQ,  Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Cancer J 2025;15:37."},{"key":"B7","series-title":"Lancet Oncol","first-page":"1317","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar SK","year":"2020","unstructured":"Kumar SK, Jacobus SJ, Cohen AD,  Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020;21:1317\u20131330."},{"key":"B8","series-title":"Lancet Haematol","first-page":"e810","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt H","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U,  Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol 2022;9:e810\u2013821."},{"key":"B9","series-title":"J Clin Oncol","first-page":"JCO2402266","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","author":"Mai EK","year":"2024","unstructured":"Mai EK, Bertsch U, Pozek E,  Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol 2024:JCO2402266."},{"key":"B10","series-title":"J Clin Oncol","first-page":"26","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt LB","year":"2024","unstructured":"Leypoldt LB, Tichy D, Besemer B,  Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol 2024;42:26\u201337."},{"key":"B11","series-title":"Blood","first-page":"Abstract 4","article-title":"Results of the phase III randomized IsKia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay F","year":"2023","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA,  Results of the phase III randomized IsKia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood 2023;142(Suppl 1):Abstract 4."},{"key":"B12","series-title":"N Engl J Med","first-page":"1597","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon T","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP,  Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;391:1597\u20131609."},{"key":"B13","series-title":"Nat Med","first-page":"2235","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu X","year":"2024","unstructured":"Leleu X, Hulin C, Lambert J,  Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med 2024;30:2235\u20132241."},{"key":"B14","series-title":"Br J Haematol","first-page":"492","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"Yimer H","year":"2019","unstructured":"Yimer H, Melear J, Faber E,  Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol 2019;185:492\u2013502."},{"key":"B15","series-title":"Blood Adv","article-title":"Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury","author":"Kim EB","unstructured":"Kim EB, Malespini JE, Lei M,  Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury. Blood Adv. Published online March 14, 2025. doi:10.1182\/bloodadvances.2025015901"},{"key":"B16","series-title":"Future Oncol","first-page":"131","article-title":"In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma","volume":"20","author":"Rifkin RM","year":"2024","unstructured":"Rifkin RM, Costello CL, Birhiray RE,  In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma. Future Oncol 2024;20:131\u2013143."},{"key":"B17","series-title":"Blood Cancer J","first-page":"147","article-title":"In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management","volume":"13","author":"Rifkin RM","year":"2023","unstructured":"Rifkin RM, Girnius SK, Noga SJ,  In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management. Blood Cancer J 2023;13:147."},{"key":"B18","series-title":"Lancet Oncol","first-page":"1705","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay F","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D,  Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 2021;22:1705\u20131720."},{"key":"B19","series-title":"J Clin Oncol","first-page":"Abstract 8001","article-title":"ATLAS: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma","volume":"40","author":"Dytfeld D","year":"2022","unstructured":"Dytfeld D, Wrobel T, Jamroziak K,  ATLAS: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma. J Clin Oncol 2022;40(16 Suppl):Abstract 8001."},{"key":"B20","series-title":"J Clin Oncol","first-page":"2946","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld P","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B,  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial. J Clin Oncol 2012;30:2946\u20132955."},{"key":"B21","series-title":"J Clin Oncol","first-page":"3921","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky R","year":"2015","unstructured":"Niesvizky R, Flinn IW, Rifkin R,  Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol 2015;33:3921\u20133929."},{"key":"B22","series-title":"N Engl J Med","first-page":"142","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart AK","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA,  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372:142\u2013152."},{"key":"B23","series-title":"Hemasphere","first-page":"e786","article-title":"Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma","volume":"6","author":"Sonneveld P","year":"2022","unstructured":"Sonneveld P, Zweegman S, Cavo M,  Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma. Hemasphere 2022;6:e786."},{"key":"B24","series-title":"Leuk Lymphoma","first-page":"833","article-title":"An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study","volume":"65","author":"Perrot A","year":"2024","unstructured":"Perrot A, Delimpasi S, Spanoudakis E,  An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leuk Lymphoma 2024;65:833\u2013842."},{"key":"B25","series-title":"Lancet Oncol","first-page":"781","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson PG","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M,  Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:781\u2013794."},{"key":"B26","series-title":"Leukemia","first-page":"1722","article-title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse","volume":"35","author":"Dimopoulos M","year":"2021","unstructured":"Dimopoulos M, Weisel K, Moreau P,  Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia 2021;35:1722\u20131731."},{"key":"B27","series-title":"N Engl J Med","first-page":"1811","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos MA","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S,  Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018;379:1811\u20131822."},{"key":"B28","series-title":"J Clin Oncol","first-page":"568","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos MA","year":"2023","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S,  Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol 2023;41:568\u2013578."},{"key":"B29","series-title":"Am J Hematol","first-page":"1595","article-title":"A phase I\/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)","volume":"96","author":"Voorhees PM","year":"2021","unstructured":"Voorhees PM, Suman VJ, Tuchman SA,  A phase I\/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol 2021;96:1595\u20131603."},{"key":"B30","series-title":"J Clin Oncol","first-page":"Abstract 8008","article-title":"A phase I\/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R\/R) multiple myeloma: initial results","volume":"34","author":"Krishnan AY","year":"2016","unstructured":"Krishnan AY, Kapoor P, Palmer J,  A phase I\/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R\/R) multiple myeloma: initial results. J Clin Oncol 2016;34(Suppl):Abstract 8008."},{"key":"B31","series-title":"Leukemia","first-page":"1567","article-title":"Phase I\/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"32","author":"Krishnan A","year":"2018","unstructured":"Krishnan A, Kapoor P, Palmer JM,  Phase I\/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed\/refractory multiple myeloma. Leukemia 2018;32:1567\u20131574."},{"key":"B32","series-title":"N Engl J Med","first-page":"335","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel J","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K,  Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389:335\u2013347."},{"key":"B33","series-title":"N Engl J Med","first-page":"1002","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero P","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B,  Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388:1002\u20131014."},{"key":"B34","article-title":"Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SoC) in lenalidomide (len)-refractory multiple myeloma (MM): phase 3 CARTITUDE-4 study update","author":"Mateos MV","unstructured":"Mateos MV, San-Migue J, Dhakal B,  Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SoC) in lenalidomide (len)-refractory multiple myeloma (MM): phase 3 CARTITUDE-4 study update. Presented at the 2024 International Myeloma Society Annual Meeting; September 25\u201328, 2024; Rio de Janeiro, Brazil."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/5\/article-p132.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/5\/article-p132.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/5\/article-p132.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T12:49:45Z","timestamp":1746708585000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/5\/article-p132.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines\u00ae"],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":34,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.0023","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}